Amylyx Pharmaceuticals (AMLX) vs IDEAYA Biosciences (IDYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 101.8% versus a gain of 34.4%. IDEAYA Biosciences is the larger company by market cap ($3.48 billion vs $3.41 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | IDYA |
|---|---|---|
| Share price | $27.20 | $36.06 |
| Market cap | $3.41B | $3.48B |
| 1-day change | -0.84% | -0.55% |
| YTD return | +125.17% | +4.31% |
| 1-year return | +101.78% | +34.35% |
| 5-year return | — | +55.90% |
| EPS (TTM) | $-1.41 | $-1.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $218.71M |
| Revenue growth (YoY) | -100.00% | +3024.43% |
| Net income (latest FY) | $-144.74M | $-113.70M |
| Operating margin | — | -72.84% |
| Net margin | — | -51.99% |
| 52-week high | $41.14 | $42.68 |
| 52-week low | $10.83 | $26.05 |
| Distance from 52-week high | -33.88% | -15.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +55.74% | +46.28% |
| Average volume | 2.35M | 779.15K |
| Shares outstanding | 125.51M | 96.49M |
| Employees | 136 | 145 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed IDYA by 67.4 percentage points over the past year.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs -100.00%).
- The two companies sit in different sectors: Amylyx Pharmaceuticals in Health Care and IDEAYA Biosciences in Healthcare.
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Healthcare · Biotechnology · 145 employees
AMLX vs IDYA FAQ
Which is bigger, Amylyx Pharmaceuticals or IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $3.48B compared with $3.41B for Amylyx Pharmaceuticals (AMLX).
Which stock has performed better over the past year, AMLX or IDYA?
AMLX returned +101.78% over the past 12 months, compared with +34.35% for IDYA (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and IDEAYA Biosciences in the same industry?
No. Amylyx Pharmaceuticals is in the Health Care sector, while IDEAYA Biosciences is in Healthcare.